Link Health: Wholly-owned subsidiary intends to purchase assets, with a transaction price of 74.5 million yuan.

Liwan Pharmaceutical Industry Announcement: Lianhuan Pharmaceutical Industry Co., Ltd., a wholly-owned subsidiary, intends to purchase a portion of buildings and land use rights from its controlling shareholder, Jiangsu Lianhuan Pharmaceutical Industry Group Co., Ltd.'s subsidiary, Prince Medical Technology Co., Ltd., for a transaction price of 74.5 million RMB. This transaction constitutes a related party transaction and does not constitute a major asset restructuring as defined by the "Management Measures for Major Asset Restructuring of Listed Companies." The transaction has been approved by the company's board of directors and supervisory board, and still needs to be submitted for approval by the company's shareholders' meeting, as well as complying with state-owned asset approval, transfer registration, and other procedures. The purpose of this transaction is to optimize resource allocation, expand asset scale, and enhance overall strength.